Elotuzumab in combination with lenalidomide and dexamethasone

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Unknown Phase

Expanded Access Treatment Protocol CA204-143

Bristol-Myers SquibbMultiple Myeloma

Updated: 2023-11-30

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

CompletedNCT06163040

Bristol-Myers SquibbRelapsed or Refractory Multiple Myeloma

Start: 2023-12-22End: 2025-03-17Updated: 2025-07-31